Aderis

Venture-backed companyucb.com

UCB a global biopharmaceutical leader focuses on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions

Rounds on record
0
More
Ask DFX about thisView relationshipsFinancing historyInvestorsOwnership and outcomes
As of · the latest observation of this company; each round carries its own date

1 additional investor

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

  1. Acquired
    observed

    Acquired by Schwarz Pharma (seen on or before Sep 13, 2026).

    seen on or before Sep 13, 2026 · A later owner ends or changes the venture chapter: new decision makers, new lenders, returns for the investors on record.

    Factpress and portfolio pagesFor Investors, acquirers, lenders, service providersOwnership and outcomes →
  2. 4 investors
    named

    4 investors on record.

    The investors already on the cap table shape who leads the next round.

    Factfunding announcements, portfolio pages and Form DFor Investors, foundersInvestors →
Drawing the relationship network…

Facts

Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
0
Disclosed raised
unknownsum of rounds with a disclosed amount only
Named investors
4

Financing history

0 rounds
No dated round yet.

Investors on record

4 edges

Ownership and outcomes

1 on record, from the private equity graph and exit reports
Outcome stated by investors

Acquired by Schwarz Pharma, as 1 of 4 firm portfolio pages states it.

Date basis: the firm’s page was read Oct 1, 2026; DFX first saw this outcome Oct 1, 2026. This is when the page said it, not when the deal happened.

Evidence: 4 listingseach firm's own card, as read
  • Acquired by Schwarz Pharma on Sanderling Management Company, LLC · the firm's card says acquired · read Oct 1, 2026 sanderling.com
    “Aderis Acquired by Schwarz Pharma”
  • Status not stated on Driven, LLC · the firm's card prints no outcome · read Sep 28, 2026 ucb.com
    “UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease.”
  • Status not stated on Length LLC · the firm's card prints no outcome · read Sep 28, 2026 ucb.com
    “The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward.”

1 more listing counted above; the firms are named with a plan.

  • Acquired by Schwarz Pharma · already an investor on record
    seen on or before Sep 13, 20264 venture investors on record at exitFactsanderling.com
    “Aderis: acquired by Schwarz Pharma on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page”

Credit relationships

none on record
No lender position matched to this company.

People

0 officers, 0 directors
No officer or director on record.

Timeline

1 event
  1. seen on or beforeSep 13, 2026
    Aderis: acquired by Schwarz Pharma on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
    Acquired Fact Firm website

Evidence

7 observations
Every observation on this company

Record history

1 identity change, 1 dated event on the change ledger, latest event first
  • Renamed
    2026-09-13
  • Acquired
    2026-09-13source on record

The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.